The Express Scripts racketeering allegations are forcing a level of scrutiny that the workers’ compensation industry can no longer ignore. Conversations across the market are centering on rebate structures, transparency, and the role financial incentives play in shaping clinical decisions. At the center of the allegations sits Ascent Health Services, a Switzerland-based entity used to route manufacturer payments in a way that may have bypassed contractual pass-through requirements. The allegations remain unproven, and industry response is underway. Leaders are reevaluating how trust, data access, and financial accountability are defined within pharmacy benefit management.
The issue centers on how manufacturer payments move through PBM contracts and how those payments are defined within financial reporting. Allegations indicate that payments labeled as administrative fees may function as rebates tied to drug utilization and formulary positioning. Employer contracts often require full rebate pass-through while allowing fees to remain with the PBM, creating a gap between contractual language and financial outcome. Federal regulators and lawmakers are increasing pressure through expanded reporting requirements and audit expectations tied to all forms of PBM compensation. Purchasers are examining contracts at the level of definitions, data fields, and payment classifications. PBM governance is measured by whether financial flows can be traced, validated, and reconciled at the drug level.
An employer may negotiate full rebate pass-through while allowing administrative fees to remain with the PBM. Payments tied to formulary placement classified as fees fall outside the pass-through structure despite direct linkage to utilization. The contract reads compliant while the financial outcome diverges. Scrutiny is now centered on the gap between definition and function.
Workers’ compensation operates within a state-regulated, medical necessity framework while relying on the same PBM infrastructure used in group health. Real-time adjudication, network pharmacy contracts, and formulary rules follow similar operational pathways across both systems. Employers and insurers contract with PBMs across multiple lines of business, allowing reputational and regulatory risk to influence vendor evaluation immediately. Developments in group health PBM practices are shaping expectations within workers’ compensation contracting and oversight. Organizations are increasing audit scrutiny, requesting claim-level data, and requiring precise definitions of all revenue streams tied to drug utilization. Procurement decisions are shifting toward data transparency and contractual enforceability.
Trust within a PBM network is defined through measurable and enforceable elements. Leaders in workers’ compensation are requiring drug-level net cost reporting, including ingredient cost, dispensing fee, and all associated manufacturer payments tied to each claim. Contract definitions of rebates extend to administrative fees, group purchasing organization payments, and third-party aggregator flows. Independent audit rights include access to rebate agreements, payment schedules, and reconciliation timelines. Conflict of interest disclosures are expanding, particularly where PBMs maintain ownership or financial relationships with affiliated pharmacies. These requirements align PBM performance with verifiable financial and clinical outcomes.
Operational risk concentrates where financial incentives intersect with clinical decision-making. Formulary placement determines access, prior authorization controls utilization, and network reimbursement influences dispensing channels. Each mechanism can be shaped by financial incentives when oversight lacks precision. Injured workers experience these dynamics through delays, redirections, or denials at the pharmacy counter. Clinical intent and financial structure must remain aligned through documented rationale and transparent governance.
An injured worker presents a prescription and receives a denial requiring prior authorization. The delay appears clinical, yet formulary placement and financial arrangements influence approval, substitution, or redirection. The worker experiences friction, the employer absorbs delay, and the claim extends. Embedded incentives shape each step when governance lacks clarity.
Financial exposure remains concentrated in specific categories rather than overall volume. High-cost topical compounds, specialty medications, and physician-dispensed drugs drive elevated claim costs when controls are insufficient. These categories often fall outside standard network pricing structures and require detailed data for oversight. Increased scrutiny of PBM financial models is likely to drive retrospective audits focused on pricing accuracy, reimbursement consistency, and payment classification. Recovery efforts tied to misclassified fees or pricing discrepancies are expected to increase. Organizations without claim-level pharmacy data lack the visibility required to manage these exposures.
Regulatory developments are reinforcing these expectations through targeted reporting and disclosure requirements. Federal legislation within the Consolidated Appropriations Act 2026 and Department of Labor rulemaking apply to ERISA-governed group health plans while reshaping PBM contracting expectations across markets. Purchasers are carrying these transparency standards into workers’ compensation relationships. State-level PBM licensing laws require disclosure of conflicts of interest, with some states explicitly including workers’ compensation programs. A consistent expectation for transparency is emerging across markets. Organizations aligning with these standards strengthen compliance readiness and market position.
The shift underway reflects a transition from vendor reliance to structured governance within workers’ compensation pharmacy programs. PBM relationships require defined financial models, validated data reporting, and enforceable audit mechanisms. Clear definitions of rebates, fees, and all associated payment streams create the foundation for control. Machine-readable data enables independent validation and continuous monitoring. Clinical governance structures documenting decision-making and disclosing conflicts strengthen alignment between financial incentives and patient care. Leadership is demonstrated through disciplined execution.
